A JAK2/IDH1-mutant MPN clone unmasked by ivosidenib in an AML patient without antecedent MPN

Myeloid neoplasm (MPN) clones can evolve from acute myeloid leukemia to gain dominance with isocitrate dehydrogenase inhibition. Pro-differentiation agents such as ivosidenib can unmask MPN sequelae.

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Blood Adv
Asıl Yazarlar: Xiao, Wenbin, Miles, Linde A., Bowman, Robert L., Durani, Vidushi, Tian, Helen S., DelGaudio, Nicole L., Mishra, Tanmay, Zhu, Menglei, Zhang, Yanming, Stump, Sarah E., Tallman, Martin S., Levine, Ross L., Cai, Sheng F.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Hematology 2020
Konular:
Exceptional Case Report
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7724900/
https://ncbi.nlm.nih.gov/pubmed/33284943
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020003326
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller